Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. - Wikidata - wikimedia - TriplyDB

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

http://www.wikidata.org/entity/Q34413432

about

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options Treating Negative Symptoms in Schizophrenia: an Update NMDA receptor modulators: an updated patent review (2013-2014)The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T.Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects.A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia.Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study.A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.Glutamate and dopamine in schizophrenia: an update for the 21st century Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example.Efficacy and Safety of Bitopertin in Patients with Schizophrenia and Predominant Negative Symptoms: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 2 Trial.Targeting of NMDA receptors in new treatments for schizophrenia.Emerging drugs for schizophrenia: an update.Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.Investigational drugs for anxiety in patients with schizophrenia.Drug repurposing and emerging adjunctive treatments for schizophrenia.Pharmacological treatment of negative symptoms in schizophrenia.Glutamatergic agents for schizophrenia: current evidence and perspectives.The impact of genetics on future drug discovery in schizophrenia.Placebo Response and Practice Effects in Schizophrenia Cognition Trials.D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition.New drug developments in psychosis: Challenges, opportunities and strategies.Insights About Striatal Circuit Function and Schizophrenia From a Mouse Model of Dopamine D2 Receptor Upregulation.Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.Conceptualization and treatment of negative symptoms in schizophrenia.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance.Extracellular glycine is necessary for optimal hemoglobinization of erythroid cells.New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor.The N-Methyl-D-Aspartate Receptor: Memory, Madness, and More.

P2860

Q22241447-E9F4F90F-2905-4A16-8571-9E9670C59B98 Q26744805-5219D0BB-FAF2-40C2-AEC6-75114D3C9AF5 Q26997407-4D7C0BF9-A9FB-442B-AA7B-AD890EE9C5DB Q28081110-DED6232C-5609-4E8A-86B1-AD6B1B0F0745 Q30490982-60D4AB0B-B9E6-4778-8F73-B6DA7391E35A Q33586550-9974142B-F3B9-4398-95D9-8E5D163F96C5 Q33624417-9FDCF437-F505-45CB-A2F4-6376245C18AA Q33842716-43177DFC-C0E2-489B-BF2A-170A67C1A571 Q34357077-F1AA320D-A463-4FE3-A71B-CAC108E71C36 Q34458090-1B1F4C42-6365-421F-BBA5-13106F562662 Q35167939-9D901DC5-FDFC-4C05-A5AE-D48F829EF0D7 Q35794290-52FBED91-4F8A-46F1-AABD-9AA84DD73A98 Q35802177-8BC4E651-5613-4DC3-84D8-644E8E83BAE1 Q35958805-6BCDC9D9-8E6E-44D2-BFBA-A92E1A8332C1 Q36642660-8D0D53EE-E6C1-4641-A599-489A05C529A9 Q36992322-5937DFF7-A636-48E3-88A9-4B54BA339ABF Q37026906-583A013D-EA46-41CC-976C-DE485ADFEAF0 Q37589466-35B82105-DAF9-465C-AD52-B65746A9A7F1 Q38223276-58B9795D-F3D6-46F7-829F-F5426B4267A6 Q38252404-CC185336-BDF4-476A-87C9-741B2286602D Q38262765-6B387DD7-74EC-422F-B595-B1DA3537E9FB Q38268878-906F9E4F-E5D4-47C7-AFDE-A0599A9B2919 Q38271298-0F0B7DF6-E718-4896-917D-B46FAF473363 Q38417631-E34CF4A4-1A7A-41D8-BFA3-C06CC3C5C3AD Q38431333-5510C9EA-78AB-48C1-B8AE-B7D8E25D3DC1 Q38444551-2F19A240-F461-41C7-BFBC-1BEB4BE0F21B Q38682213-247A7DBB-5C36-4E37-9DB1-0FCDBA64F305 Q38715567-C09C8581-E06C-48A9-B29E-6EE0EC8A9902 Q38750121-2B3A3044-D2A2-44F8-99AA-D1F435F4540E Q38897362-91A0DBA3-1B26-4D46-B80D-08515D1778E1 Q38926246-94AC866A-B5A1-41BE-A872-14B890C95304 Q38976397-A56BF087-9FF1-4B26-BD3F-ED8F28E8EBEE Q39062177-1FFE3395-ECA6-4886-9700-9D20D28DFA93 Q39178474-012B73F7-CF40-429F-B64A-8D3CFF000CFA Q39233330-4091C41F-22FE-4D91-8B2F-B3B5F7311F73 Q39788584-34B1B8BB-CEEE-4589-A340-9333A3D2B6BF Q41230295-D765F414-C2A4-48E8-A6F2-C9B775A10DE7 Q41573540-9CFCB9CB-7796-4F47-ACF5-FCD3FA1F4813 Q46308311-302DEC61-CDAA-4CF9-A17A-7F69E6AFD1DE Q47142975-51CDF3B7-ACC4-4004-AF4F-2AEE007939C7

P2860

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

http://www.wikidata.org/entity/Q34413432

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@ast

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@en

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@nl

type

label

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@ast

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@en

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@nl

prefLabel

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@ast

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@en

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@nl

P1433

Q34413432-A82B8F23-0BC7-4E84-B3C0-B9579FCE4338

P1476

Q34413432-9135F253-8FFF-48FA-8FF3-6AB45D67D02E

P2093

Q34413432-14DEB0AA-AA03-49FF-AA53-7FD764B21FA3

Q34413432-1FE4578F-CE43-4104-A746-0E44F0F8F48B

Q34413432-37EA9409-040A-4F4D-8F27-8C138F7F1CC4

Q34413432-3FC6F1AE-8850-469A-ADD7-E5AEF66FB4EA

Q34413432-443CA209-0423-4707-93AB-80259254C12F

Q34413432-4CC22CB8-DCAC-4958-908C-96CF1FB3EEC9

Q34413432-694848E8-A770-410F-B1F6-A878F2DC778C

Q34413432-7E2521B3-DA01-47A2-BEBA-98E6E541B32F

Q34413432-833F5572-804A-41B0-9D05-0986583628FF

Q34413432-884F3815-BF6A-40B7-BBDD-E62022844EE3

P304

Q34413432-CF872DED-43D5-4A35-B2D3-F6487CED04F6

P31

Q34413432-D34FB1B8-71B4-4778-AC7B-7609C4093391

P356

Q34413432-F7CA29FD-6E78-418E-9B58-D4949BF10177

P407

Q34413432-64C0C51C-3175-4AF8-A252-57AE258A301C

P433

Q34413432-276882AF-4967-47C1-9F3D-4E25EE321289

P478

Q34413432-C352A9D3-10DE-46C4-BBAC-D987C7B77648

P577

Q34413432-13E87C00-2A3B-4478-B08C-7DB0CAAF0C0B

P5875

Q34413432-B8F617DA-4DD9-4568-9A80-A66FC078E523

P698

Q34413432-AA35CFAE-46A6-4D10-9C2A-3F1288EC2AAA

P921

Q34413432-7BF357DC-B417-4BFC-A668-0AB9898FEF62

P356

JAMAPSYCHIATRY.2014.163

P1433

JAMA Psychiatry

P1476

Effect of bitopertin, a glycin ...... blind, proof-of-concept study.

@en

P2093

Alexander Bausch

http://www.w3.org/2001/XMLSchema#string

Daniel Umbricht

http://www.w3.org/2001/XMLSchema#string

Daniela Alberati

http://www.w3.org/2001/XMLSchema#string

Edilio Borroni

http://www.w3.org/2001/XMLSchema#string

Eriene A Youssef

http://www.w3.org/2001/XMLSchema#string

Ernest Dorflinger

http://www.w3.org/2001/XMLSchema#string

Frédéric Knoflach

http://www.w3.org/2001/XMLSchema#string

George Garibaldi

http://www.w3.org/2001/XMLSchema#string

Joseph G Wettstein

http://www.w3.org/2001/XMLSchema#string

Luca Santarelli

http://www.w3.org/2001/XMLSchema#string

P304

637-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAPSYCHIATRY.2014.163

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261328109

http://www.w3.org/2001/XMLSchema#string

P698

24696094

http://www.w3.org/2001/XMLSchema#string

P921